RxDoctor Payments Data

Khaula Khalid, DO

Cardiovascular Disease · Glen Ridge, NJNPI 1164698445

Payments from drug & device makers

$2,130in general payments, 2019–2025

Across 102 payments — averaging $20.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$478
  • Amgen$333
  • Merck$258
  • Novo Nordisk$233
  • AstraZeneca$220
  • Novartis$216
  • plus $393 from 11 others

What the payments were for

  • Food & beverage$2,130100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,130 in reported general payments places this provider in the 40th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$164,796
Medicare patients
179
Services billed
1,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide126$127,187
EliquisApixaban127$106,992
Repatha SureclickEvolocumab79$61,319
BrilintaTicagrelor78$49,340
MounjaroTirzepatide28$35,834
FarxigaDapagliflozin Propanediol37$24,013
XareltoRivaroxaban18$18,813
EntrestoSacubitril/Valsartan20$16,709
JardianceEmpagliflozin15$15,954
JanuviaSitagliptin Phosphate12$8,037
Rosuvastatin Calcium490$7,656
Metoprolol Succinate335$3,545
Nifedipine ErNifedipine163$3,246
Losartan Potassium310$2,580
Atorvastatin Calcium247$2,401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$233$127,187126 claims
PfizerEliquis$27$106,992127 claims
AstraZenecaBrilinta, Farxiga$220$73,352115 claims
Lilly USA, LLCMounjaro$174$35,83428 claims
Johnson & JohnsonXarelto$14$18,81318 claims
NovartisEntresto$216$16,70920 claims
Boehringer IngelheimJardiance$16$15,95415 claims
MerckJanuvia$258$8,03712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Glen Ridge

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →